BFM
MAZE

Boothbay Fund Management’s Maze Therapeutics MAZE Stock Holding History

Boothbay Fund Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.49M Sell
284,476
-124,896
-31% -$5.51M 0.11% 176
2025
Q4 		$17M Buy
409,372
+57,497
+16% +$1.98M 0.25% 62
2025
Q3 		$9.12M Buy
351,875
+276,345
+366% +$4.67M 0.13% 177
2025
Q2 		$927K Sell
75,530
-21,438
-22% -$223K 0.02% 706
2025
Q1 		$1.07M Buy
+96,968
New +$1.17M 0.03% 606

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Boothbay Fund Management's MAZE Position: Q1 2026 in Review

Boothbay Fund Management reduced its Maze Therapeutics (MAZE) stake by 31% in Q1 2026, selling an estimated $5.51M and leaving 284,476 shares worth $8.49M. The position accounts for 0.11% of the portfolio, ranked #176.

Boothbay Fund Management first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $17M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Boothbay Fund Management held 284,476 shares of Maze Therapeutics worth $8.49M as of Q1 2026.
  • Boothbay Fund Management sold 124,896 Maze Therapeutics shares in Q1 2026, an estimated $5.51M.
  • Maze Therapeutics made up 0.11% of Boothbay Fund Management's portfolio in Q1 2026, its #176 holding.
  • Boothbay Fund Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Boothbay Fund Management's Maze Therapeutics position peaked at $17M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.